Principal Financial Group
ARCT icon

Principal Financial Group’s Arcturus Therapeutics ARCT Stock Holding History

Principal Financial Group’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-16,674
Closed -$406K – 2237
2024
Q2 		$406K Sell
16,674
-842
-5% -$25.5K ﹤0.01% 2003
2024
Q1 		$592K Buy
17,516
+10,454
+148% +$370K ﹤0.01% 1949
2023
Q4 		$223K Buy
+7,062
New +$168K ﹤0.01% 2138
2021
Q4 		– Sell
-5,138
Closed -$245K – 2534
2021
Q3 		$245K Sell
5,138
-832
-14% -$37.3K ﹤0.01% 2373
2021
Q2 		$202K Buy
5,970
+553
+10% +$18.7K ﹤0.01% 2477
2021
Q1 		$224K Sell
5,417
-5,193
-49% -$310K ﹤0.01% 2350
2020
Q4 		$460K Buy
+10,610
New +$719K ﹤0.01% 2131

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principal Financial Group's ARCT Position: Q3 2024 in Review

Principal Financial Group sold out of Arcturus Therapeutics (ARCT) in Q3 2024, closing a stake of 16,674 shares — an estimated $406K sold.

Principal Financial Group first reported a position in ARCT in Q4 2020 and held it in 7 quarters. The position peaked at $592K in Q1 2024. 164 funds tracked by Wall St. Rank hold ARCT as of Q3 2024.

  • Principal Financial Group reported no remaining Arcturus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Principal Financial Group sold 16,674 Arcturus Therapeutics shares in Q3 2024, an estimated $406K.
  • Principal Financial Group first reported a position in Arcturus Therapeutics in Q4 2020 and held it in 7 quarters.
  • Principal Financial Group's Arcturus Therapeutics position peaked at $592K in Q1 2024.
  • 164 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2024.

Based on Principal Financial Group's 13F filing for Q3 2024, filed 31 Oct 2024.